Citi added an “upside 90-day catalyst watch” on Kymera Therapeutics (KYMR) while keeping a Buy rating on the shares with an $80 price target Citi sees a favorable risk/reward on the shares into the Phase 1b study data for KT-621 in atopic dermatitis. Citi expects the data readout in mid-to-late November.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on KYMR:
- Nurix Therapeutics price target lowered to $21 from $22 at Wells Fargo
- Kymera Therapeutics price target raised to $75 from $59 at BTIG
- Kymera Therapeutics initiated with an Outperform at Mizuho
- Kymera Therapeutics price target raised to $80 from $60 at Citi
- Nurix Therapeutics price target lowered to $22 from $25 at Wells Fargo